Hemi-thoracic irradiation with proton therapy in malignant pleural Mesothelioma (HIT-Meso) sub-study
HIT-Meso is a clinical trial led by Consultant Clinical Oncologist, Dr Crispin Hiley and based at the UCL Cancer Institute. You can see details of the main clinical trial on the UCL website.
HIT-Meso aims to find out how well a new therapy, called Proton Beam Therapy, can be used to treat pleural mesothelioma patients. Proton Beam Therapy is a type of medical treatment that uses high energy protons to deliver a very precise and powerful dose of radiation to cancer cells. This treatment may avoid some side effects associated with other types of radiation therapy because fewer healthy cells will be damaged.
In parallel with the main study, our team will be conducting a qualitative sub-study. This will aim to evaluate the patient experience of receiving the Proton Beam Therapy and trial processes.
The study aims to answer the following research questions:
- What are patient expectations of the HIT-MESO trial and Proton Beam Therapy treatment?
- What is the patient experience of receiving the Proton Beam Therapy intervention?
- What is the patient experience of the HIT-MESO trial process? What factors influence patient decisions regarding HIT-MESO including participation and randomisation?
We will recruit 8-10 people who are randomised to receive the Proton Beam Therapy. These 8-10 participants will be asked to complete a survey before they receive the treatment and take part in an interview after they have received the treatment.
For more information about this study, please contact Dr Beth Taylor (btaylor3@sheffield.ac.uk), or Professor Clare Gardiner (c.gardiner@sheffield.ac.uk).